November 2013

Dr. Lynora Saxinger, MD FRCPC CTropMed
Infectious diseases, University of Alberta Hospital, co-Chair of the Alberta Health Services Antimicrobial Stewardship Committee, Chair of the Antimicrobial Stewardship and Resistance Committee of AMMI Canada

The theme of the November 2013 webinar was: Tracking, assessing and reacting: Surveillance as a tool in controlling Antimicrobial Resistance, in Canada and globally.

When physicians treat patients with “cold and flu” symptoms with antibiotics, people often…. get better.  This can be because the antibiotic worked well for a bacterial sinusitis or bronchitis, or MUCH more commonly, because their immune system defeated the disease causing organism,  likely a virus – or less commonly, a resistant bacteria.  A smattering of resistant bacteria cases can easily be unnoticed in a busy office- unless there is an attempt to measure what is happening with the population.  Attempts to monitor and control communicable diseases goes back to the Venetian practice of 40 days of isolation for ships at harbor (quaranta – fourty- quarantine) in the days of Black Plague in Europe.

In this session, we will examine international and Canadian programs of Antimicrobial Resistance and Utilization surveillance through the lens of what is thought to be “ideal”, and look at how improved data can link to optimal action for public health.

TRANSCRIPT of the WEBINAR: Download it here




November 14 and 16, 2012

Thank you to Dr. Donald Low, and to the Public Health Agency of Canada, who gave webinar presentations during Antibiotic Awareness Week.

Session 1: November 14

The Menace of Antimicrobial Resistance


Chief of the Department of Microbiology, University Health Network and Mount Sinai Hospital, Professor at the University of Toronto, Department of Laboratory Medicine and Pathobiology and Department of Medicine.

Infections with resistant bacteria were first reported in the early part of the last century with the use of optochin to treat pneumococcal pneumonia. Early on the problem was often overlooked, because if one antibiotic did not treat the infection another was usually available. Since then, infections with resistant bacteria have become more common in healthcare and community settings, and many bacteria have become resistant to more than one type or class of antibiotics. Consequently, health care workers are faced with treating infections where antibiotic options are very limited, and in some cases, where no effective antibiotics exist. The consequences of resistance are many including: need to use antibiotics that are more expensive or more toxic; the risk of increased morbidity and mortality; failure to effectively treat, the microorganisms will persist and potentially spread to others; and the economic burden on the healthcare system. We are currently witnessing a number of new emerging threats that will challenge how we care for our patients including pan-resistant gram-negatives pathogens in both the hospital (NDM-1, MRSA), the community (multi-drug resistant gonorrhoea, MRSA, multidrug-resistant pneumococci), and in agriculture (Multidrug-resistant DT 104 Salmonella Typhimurium).

Session 2: November 16

Antimicrobial Resistance: Perspectives from the Public Health Agency of Canada – WATCH THE RECORDING or READ THE TRANSCRIPT

Learn more about activities carried out on antimicrobial resistance and antimicrobial use by the Public Health Agency of Canada and the direct impact these are having on public health practice.

Marc-André Gaudreau
Manager, Strategic Issues, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada.

An overview of the Agency’s role with respect to antimicrobial resistance will be provided. Download PDF


Monitoring AMR from farm to fork – results from the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) Download PDF

Rita Finley
Senior Epidemiologist, Surveillnce Division of the Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada.

Following antimicrobial resistant Salmonella isolated from farm, abattoir, retail and human clinical cases. Ms Finley will also share updates on the human antimicrobial use surveillance that is carried out by CIPARS.


Antimicrobial Resistant Neisseria gonorrhoeae in Canada: a National Perspective Download PDF

Irene Martin
Head, Streptococcus and STI Unit, National Microbiology Laboratory, Public Health Agency of Canada

In Canada, reported rates of gonorrhea infection have been increasing yearly since 1997. Neisseria gonorrhoeae isolates with decreasing susceptibilities to the cephalosporins used for treatment are on the rise, threatening the available drug treatment options for gonorrhea infections.  The Public Health Agency of Canada’s National Microbiology Laboratory monitors the antimicrobial susceptibilities of N. gonorrhoeae to ensure the effectiveness of recommended treatments and timely detection of emerging resistance mechanisms.


Public Health Updates on the Management of multidrug resistant gonorrhea (MDR-GC) Download PDF

Dr. Thomas Wong, MD, MPH, CCFP, FRCPC
Director of Professional Guidelines and Public Health Practice Division, Centre for Communicable Diseases & Infection Control, Public Health Agency of Canada

Dr. Wong will share treatment recommendations from the Canadian Guidelines on Sexually Transmitted Infections that have been updated in response to increasing gonococcal antimicrobial resistance.

 Webinars 2011

Monday, November 14, 2011


  • David Butler-Jones, Chief Public Health Officer, Public Health Agency of Canada
  • Craig Stephen, Faculty of Veterinary Medicine, University of Calgary

Tuesday, November 15, 2011



  • Daniel Thirion, Faculty of Pharmacy, University of Montréal
  • Aboubakar Mounchili, Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada

Thursday, November 17, 2011

  • Rita Finley, Centre for Food-borne, Environmental and Zoonotic Infectious Diseases, Public Health Agency of Canada
  • Lynora Saxinger, Antibiotic Stewardship Committee, Division of Infectious Diseases, University of Alberta
  • Daniel Thirion, Faculty of Pharmacy, University of Montréal

Watch the 2010 Antibiotic Awareness Day Webinar Archives